ESTRO 2025 - Abstract Book

Brachytherapy - Gastro-intestinal, paediatric brachytherapy, miscellaneous

S194

ESTRO 2025

first treatment. EORTC QLQ-C29 and Vaizey Incontinence questionnaires assessed bowel function at baseline and at 3-monthly intervals. Decision regret scores were calculated out of 100, with higher scores corresponding to greater regret. Patients who received CXB and completed 1 year of follow-up were included for analysis. Results: Twenty-two patients who underwent CXB were identified. Sixteen were T1/2 and six were T3/4. Twelve received chemoradiotherapy with CXB, 9 external beam radiotherapy with CXB and 2 only CXB. Baseline faecal incontinence to liquids occurring “sometimes” or more frequently was reported by 4.7%. of patients. Two months post-treatment, this rose to 33.3% and was 41.2% at 11 months. 76.5% of patients reported faecal urgency at 11 months compared to 52.4% at baseline. The mean Vaizey Score at baseline was 5.8, rising to 9.8 by 11 months. 63.6% were pain free at baseline. After treatment, 25% were pain free at one month, but 73.3% by 10 months. 81.8% of patients experienced bleeding pre-CXB. At 10 months, 60% reported only “a little” bleeding. Mucus discharge occurred in 81.3% at 4 months and was still present in 71.4% by 10 months. At their baseline, 47.6% of patients reported that their bowel symptoms “sometimes” or more frequently affected their lifestyle compared to 52% at 11 months. However, 23.5% reported a daily impact on lifestyle at 11 months compared to 14.3% prior to treatment. The mean decision regret scores remained low from 2- to 11-months (6.3 to 7.8/100.)